James P Mackin sold $2.2M of AORT
President & CEO at ARTIVION, INC.. 88,439 shares at an average of $24.77, traded Mar 6, 2025, filed Mar 10, 2025.
Score components
- +25RoleCEO
- +25Trade size$2.2M at market
- +5Share of holdings soldSold 10% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000784199-25-000057, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 6, 2025 | AGrant or award Common Stock10b5-1 | +115,701 | $0.00 | $0 | 878,107 | Mar 10, 2025 |
| Mar 6, 2025 | SOpen-market sale Common Stock10b5-1 | -17,739 | $24.80 | $440k | 860,368 | Mar 10, 2025 |
| Mar 6, 2025 | MOption exercise Common Stock10b5-1 | +75,615 | $21.55 | $1.6M | 935,983 | Mar 10, 2025 |
| Mar 6, 2025 | SOpen-market sale Common Stock10b5-1 | -70,700 | $24.76 | $1.8M | 865,283 | Mar 10, 2025 |
| Mar 6, 2025 | MOption exercise Stock Options (Right to buy)derivative10b5-1 | -75,615 | $0.00 | $0 | 0 | Mar 10, 2025 |
Related signals
Other insiders at ARTIVION, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 34Weak | AORTsell ARTIVION, INC. | Andrew M Green SVP, Regulatory and Quality | $287k 11,480 shares | -22% | |
| 32Weak | AORTsell ARTIVION, INC. | Andrew M Green SVP, Regulatory and Quality | $216k 8,003 shares | -13% | |
| 17Weak | ARTIVION, INC. | Marshall S. Stanton SVP, Clinical & MD Affair | $443k 15,000 shares | -19% | |
| 21Weak | ARTIVION, INC. | Marshall S. Stanton SVP, Clinical & MD Affair | $743k 26,132 shares | -25% | |
| 38Weak | ARTIVION, INC. | Anthony B. Semedo director | $74k 2,600 shares | -7% | |
| 36Weak | ARTIVION, INC. | Jean F Holloway SVP, General Counsel | $254k 8,748 shares | -5% | |
| 44Moderate | ARTIVION, INC. | Jean F Holloway SVP, General Counsel | $288k 9,926 shares | -5% | |
| 44Moderate | ARTIVION, INC. | Marshall S. Stanton SVP, Clinical & MD Affair | $307k 10,548 shares | -9% | |
| 10Weak | ARTIVION, INC. | John E Davis Chief Commercial Officer | $357k 15,100 shares | -7% | |
| 12Weak | ARTIVION, INC. | Jean F Holloway SVP, General Counsel | $426k 18,020 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.